Investigação de parâmetros de inflamação e estresse oxidativo em pacientes com diabetes mellitus tipo 2 usuários e não usuários de insulinoterapia

• Ano de defesa: 2017
• Autor(a) principal: Paiva, Kainá Kiffer
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal do Espírito Santo; BR; Mestrado em Ciências Farmacêuticas; Centro de Ciências da Saúde; UFES; Programa de Pós-Graduação em Ciências Farmacêuticas
• Palavras-chave em Português: Diabetes mellitus type 2; Insulin; Metabolic control; Inflammation; Oxidative stress; Diabetes mellitus tipo 2; Controle metabólico; Estresse oxidativo; Diabetes; Insulina; Inflamação; Stress oxidativo; Farmácia; 612
• Link de acesso: http://repositorio.ufes.br/handle/10/8352

Type 2 diabetes mellitus (DM2) is a metabolic disorder resulting from hyperglycemia and insulin resistance which is characterized by increased production of reactive species leading to oxidative stress and inflammatory changes. The goal of this study was to investigate whether the use of insulin therapy in patients with Type 2 Diabetes Mellitus influences levels of inflammatory markers and oxidative stress. It is a clinical study in which 80 patients diagnosed with T2DM (40 in insulin therapy and 40 without insulin therapy) and 40 in the control group (without DM2) were selected. Adherence to treatment was assessed by the Morisky-Green test. Metabolic control was evaluated through tests of fasting glycemia, glycated hemoglobin and lipid profile. Oxidative stress was investigated through levels of nitric oxide (NO), lipid peroxidation (Malondialdehyde - MDA) and superoxide dismutase (SOD). The inflammation evaluation was performed through the markers: tumor necrosis factor alpha (TNFα), ultra sensitive C reactive protein (CRP) and fibrinogen. In addition, the -308 G / A polymorphism was investigated in the promoter region of the TNFα gene and its correlation with its plasma levels. In this study, an inadequate glycemic control was found in patients with DM2 who were on insulin therapy and a low adherence to treatment in both DM2 groups (approximately 50% of the patients). The DM2 group with insulin therapy had lower levels of NO and SOD, higher levels of fibrinogen and TNF-α, and lower levels of CRP than the DM2 group without insulin therapy. In lipid peroxidation both groups of patients with DM2 had higher levels of MDA than controls. There was no correlation of the -308 G / A polymorphism in the promoter region of the TNF-α gene with its plasma levels in patients with T2DM. In conclusion, patients with DM2, who are users or not of insulin therapy, have increased oxidative stress and inflammation, which may contribute to the various complications of the disease.